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ABSTRACT
Objectives: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was
designed to evaluate the conventional NSAID naproxen sodium and the selective COX-2
inhibitor celecoxib for primary prevention of Alzheimer’s dementia (AD). On 17 December 2004,
after the Adenoma Prevention with Celecoxib (APC) trial reported increased cardiovascular risks
with celecoxib, the ADAPT Steering Committee suspended treatment and enrollment. This
paper reports on cardiovascular and cerebrovascular events in ADAPT.
Design: ADAPT is a randomized, placebo-controlled, parallel chemoprevention trial with 1–46
mo of follow-up.
Setting: The trial was conducted at six field sites in the United States: Baltimore, Maryland;
Boston, Massachusetts; Rochester, New York; Seattle, Washington; Sun City, Arizona; and
Tampa, Florida.
Participants: The 2,528 participants were aged 70 y and older with a family history of AD.
Interventions: Study treatments were celecoxib (200 mg b.i.d.), naproxen sodium (220 mg
b.i.d.), and placebo.
Outcome measures: Outcome measures were deaths, along with nonfatal myocardial
infarction (MI), stroke, congestive heart failure (CHF), transient ischemic attack (TIA), and
antihypertensive treatment recorded from structured interviews at scheduled intervals. Cox
proportional hazards regression was used to analyze these events individually and in several
composites.
Results: Counts (with 3-y incidence) of participants who experienced cardiovascular or
cerebrovascular death, MI, stroke, CHF, or TIA in the celecoxib-, naproxen-, and placebo-treated
groups were 28/717 (5.54%), 40/713 (8.25%), and 37/1070 (5.68%), respectively. This yielded a
hazard ratio (95% confidence interval [CI]) for celecoxib of 1.10 (0.67–1.79) and for naproxen of
1.63 (1.04–2.55). Antihypertensive treatment was initiated in 160/440 (47.43%), 147/427
(45.00%), and 164/644 (34.08%). This yielded hazard ratios (CIs) of 1.56 for celecoxib (1.26–1.94)
and 1.40 for naproxen (1.12–1.75).
Conclusions: For celecoxib, ADAPT data do not show the same level of risk as those of the
APC trial. The data for naproxen, although not definitive, are suggestive of increased
cardiovascular and cerebrovascular risk.
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PLoS CLINICAL TRIALSINTRODUCTION
Epidemiological studies suggest that nonsteroidal anti-in-
ﬂammatory drugs (NSAIDs) may delay or prevent the onset of
Alzheimer’s dementia (AD). A recent meta-analysis of three
prospective studies indicated a relative hazard (with 95%
conﬁdence interval [CI]) of 0.42 (0.26–0.66) among individuals
with 2 y or more of sustained NSAID treatment, compared to
nonusers [1]. The Alzheimer’s Disease Anti-inﬂammatory
Prevention Trial (ADAPT) was designed to investigate
whether the nonselective NSAID naproxen sodium (Aleve,
from Bayer, Leverkusen, Germany) or the selective cyclo-
oxygenase-2 (COX-2) inhibitor celecoxib (Celebrex, from
Pﬁzer, New York, New York, United States) can prevent AD
or delay cognitive decline.
On Friday, 17 December 2004, increased cardiovascular
risks with celecoxib were reported from the National Cancer
Institute-sponsored Adenoma Prevention with Celecoxib
(APC) trial. On the same day, the ADAPT Steering Committee
suspended treatment with celecoxib as well as with naproxen.
Suspension of naproxen reﬂected the ADAPT investigators’
reluctance to imply, by continuing the trial, that naproxen
was safer than celecoxib when ADAPT data did not support
this conclusion. Our rationale for suspending both treat-
ments in ADAPT was more fully discussed in our 18 February
2005 testimony to the Food and Drug Administration (FDA)
Arthritis Advisory Committee and the Drug Safety and Risk
Management Advisory Committee [2].
This report describes the structure of ADAPT and presents
the trial’s safety data through the end of the treatment
period. We offer our interpretation of these data in their
context, that is, for a trial that was not designed or powered
for cardiovascular or cerebrovascular events as primary
outcomes and, additionally, was stopped early. We believe
we are obligated to make these results available to the
scientiﬁc community and the public at large, and we present
them as a contribution to the larger body of evidence about
the potential cardiovascular and cerebrovascular risks of
COX-2 inhibitors and conventional NSAIDs.
METHODS
Study Design
ADAPT is a randomized, placebo-controlled, multicenter,
primary prevention trial. It is investigator-initiated and
sponsored by the National Institute on Aging (NIA) via a
cooperative agreement. All pertinent institutional review
boards approved the study protocol.
Participants
Recruitment was accomplished primarily through mailings to
Medicare beneﬁciaries targeted by age and by ZIP code to
areas surrounding the trial’s six ﬁeld sites in the United States
(Baltimore, Maryland; Boston, Massachusetts; Rochester, New
York; Seattle, Washington; Sun City, Arizona; and Tampa,
Florida). Eligibility criteria included being the age of 70 y or
older and having a history of at least one ﬁrst-degree relative
with Alzheimer-like dementia. Participants underwent cog-
nitive screening to exclude those with dementia or other
cognitive disorders. Persons regularly using NSAIDs were
excluded. Use of aspirin was allowed at 81 mg per day or less.
More speciﬁc information on eligibility criteria is available
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Editorial Commentary
Background: Evidence from observational studies suggests that people
taking certain nonsteroidal anti-inflammatory drugs (NSAIDs) are at
lower risk of developing Alzheimer’s disease. However, in order to
reliably find out whether NSAIDs reduce the risk of Alzheimer’s, it is
important to perform a properly designed randomized trial. Such a trial,
ADAPT, was sponsored by the United States National Institute on Aging,
and the study started recruitment in 2001. The trial involved three
treatment arms: naproxen (one type of NSAID), celecoxib (another type
of NSAID, but one that specifically inhibits an enzyme called COX-2), and
placebo, acting as a control. It was planned that 2,625 participants would
be recruited and that the primary outcome of interest was incidence of
Alzheimer’s disease in the three treatment arms; the trial would run for 7
y. However, this trial was terminated early, a decision based in part on
information from other studies that demonstrated an increased risk of
certain harms, such as heart attacks and strokes, in people taking
celecoxib and other types of COX-2 inhibitors. Therefore meaningful data
were not available at the time on the study’s primary outcome
(prevention of Alzheimer’s disease). However, data about the chance of
these harms are available from the ADAPT results, and these results are
presented here.
What this trial shows: The investigators compared frequency of
particular types of harm in the treatment arms: heart attack, stroke,
congestive heart failure (CHF), and transient ischemic attack (TIA). For
each individual type of event, some were more likely in people treated
with celecoxib compared with placebo, but others were not. When
considering people taking naproxen, all four types of adverse events
were more likely to occur in the treatment group as compared to
placebo. The investigators then combined data from all four types of
harm together, and here they found that the overall risk in people taking
celecoxib was higher than for people taking placebo, but that this was
not statistically significant, so it could have been due to chance alone.
When considering naproxen as compared with placebo, the researchers
saw an approximately 60% increase in risk for all four harms combined,
and this result was statistically significant. The death rate in people
taking either celecoxib or naproxen was higher than for those taking
placebo, but this was not statistically significant, and therefore could
have been due to chance.
Strengths and limitations: Strengths of this study include the
randomization procedures, which used a distributed computer system to
assign patients to treatment arms (minimizing the chance of bias),
blinding of patients to their treatment assignment, and blinding of the
committee reviewing deaths and safety reports to treatment assignment.
One limitation is that although the trial was large and appropriately
powered for the main outcome (prevention of Alzheimer’s disease), the
number of safety events reported here were small and the trial was not
primarily designed to examine safety. Further, participants eligible to join
this trial were required to have a family history of Alzheimer’s disease, so
it is possible that their risk factors are slightly different from the general
population.
Contribution to the evidence: The cardiovascular safety of NSAID’s,
including COX-2 inhibitors, is an intensely debated topic. Very few
published data exist on the long-term safety of celecoxib as compared
with placebo, although there are a number of as-yet-unpublished
studies. These data on harms provided by ADAPT provide important
results that should be incorporated into future meta-analyses. Such
meta-analyses will give a more rigorous and reliable assessment of the
safety of the drugs studied here.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.from the trial’s protocol (available at http://www.jhucct.com/
adapt/manall43.pdf). Written consent was obtained from each
participant.
Interventions
Participants were randomly assigned to receive celecoxib (200
mg b.i.d.), naproxen sodium (220 mg b.i.d.), or placebo.
Randomization—Sequence Generation
The randomization sequence was generated by the trial’s
coordinating center in permuted blocks stratiﬁed by three
age groups (ages 70–74, ages 75–79, and ages 80þ) and the six
ﬁeld sites, with an assignment ratio of 1:1:1.5.
Randomization—Allocation Concealment
Treatment assignment was in the form of an allocation to one
of 49 bins (14 containing celecoxib and placebo matched to
naproxen, 14 containing naproxen and placebo matched to
celecoxib, and 21 containing placebos matched to celecoxib
and naproxen). The bin system simpliﬁed long-term supply of
study drug, and the number of bins reduced the risk of
unmasking large numbers of participants. Only select
coordinating center personnel knew the correspondence of
bin allocation to treatment assignment.
Randomization—Implementation
Randomization was implemented via computer systems
distributed to each of the six sites. The sequence of bin
assignments was concealed from site personnel via encoding
and password protection of the randomization ﬁles. Before
randomization, site personnel were required to enter baseline
data. The ADAPT computer system conﬁrmed eligibility
before releasing the bin assignment.
Masking
Masking of participants and ﬁeld site personnel was achieved
using a double placebo design [3]; each bin, as described
above, contained both celecoxib or matching placebo, in the
form of white capsules in white-labeled bottles, and naproxen
or matching placebo, in the form of blue tablets in blue-
labeled bottles. The placebos were provided by the manu-
facturers of the active drugs and were not distinguishable
from them.
Sample Size
Sample size calculations were performed using a SAS macro
by Shih [4] for time-to-event outcomes. The sample size
provided 80% power to detect a 30% reduction in the risk of
AD over up to 7 y of follow-up, based upon parameter
assumptions outlined in the trial’s protocol.
Data Collection
Studyclinicianscollecteddatathroughin-personinterviewsof
participants 1 mo and 6 mo after randomization and then
every 6 mo thereafter. Similarly constructed telephone inter-
views with participants were conducted every 6 mo in the
intervals between in-person visits, starting at month 3. During
theseroutinevisitsandcalls,maskedstudypersonnelrecorded
participant reports of adverse events on data forms. When
indicated, according to clinical judgment, they clariﬁed these
self-reported events with participants’ primary care physi-
cians. All fatal events also were reported in real time on death
reports, and death certiﬁcates were obtained when possible.
Outcomes
The outcomes we report here are adverse events, including
occurrences of death, myocardial infarction (MI), stroke,
congestive heart failure (CHF), and transient ischemic attack
(TIA). Fatal events were obtained from death reports, and
nonfatal events were determined from scheduled follow-up
interviews. Deaths are included if they occurred on or before
17 January 2005 (1 mo after suspension of treatment) and
were reported by 1 July 2005. An internal committee of three
physicians, who were masked to treatment assignment,
reviewed all events with details recorded on death reports
to classify the fatal events. Events reported during scheduled
follow-up contacts are included if they were recorded by 17
April 2005 (to allow an additional 90-d window for routine
follow-up) and keyed into the ADAPT database by 1 July 2005.
Composite outcomes were created in a manner similar to that
of the APC trial (that is, by sequentially supplementing
cardiovascular and cerebrovascular deaths with categories of
nonfatal events) [5]. We combined these deaths sequentially
with nonfatal MI, stroke, CHF, and TIA and for each
composite outcome analyzed the time to the ﬁrst event. The
composite outcome of cardiovascular or cerebrovascular
death, MI, or stroke also is similar to that used by the
Antiplatelet Trialists Collaboration [6].
We also analyzed new occurrences of treatment for
hypertension among participants not receiving treatment
for hypertension at baseline. This information was obtained
by participant report at routine data collection times.
Statistical Methods
Percentages of participants experiencing the events of
interest were calculated by assigned treatments. Analyses of
time to ﬁrst occurrences of events were performed using Cox
proportional hazards regression, and hazard ratios were
estimated with 95%CI and Wald p-values. Analyses of deaths
included all participants, with censoring during follow-up of
individuals with unknown vital status. Analyses of events
ascertained at scheduled follow-up excluded participants with
no follow-up data collection and censored those lost to follow-
up. Active treatments were compared individually with
placebo, but not with one another. The Kaplan-Meier method
was used to graph the incidence of the composite outcome.
Secondary analyses considered events occurring while partic-
ipants were being issued the study drug, and events were
stratiﬁed by baseline use of aspirin for cardioprotection. All
analyses were conducted with SAS version 8.1.
Data Monitoring
The trial’s Treatment Effects Monitoring Committee met in
person twice a year to review efﬁcacy and safety data
classiﬁed by treatment assignment. The committee, compris-
ing four independent voting members and three nonvoting
members from the trial (the NIA project ofﬁcer, the director
of the coordinating center, and a study consultant with
special expertise in AD epidemiology), was advisory to the
Steering Committee and the NIA.
RESULTS
Participant Flow and Recruitment
The ﬂow of participants through randomization, follow-up,
and analysis is diagramed in Figure 1. Enrollment com-
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participants had been enrolled. Of these, 98.4% received
their assigned study treatment.
Baseline Data
Table 1 provides baseline and demographic characteristics by
treatment group. More men than women were enrolled. Race/
ethnicity was predominantly Caucasian. Over three-quarters
of the population had post-high school education. Medical
history included an uncomplicated peptic ulcer or MI for
small percentages of participants. Current smoking was rare.
These baseline characteristics were similar for the three
treatment groups, with the exception of a somewhat greater
proportion of prior smokers in the placebo-treated group.
Numbers Analyzed, Follow-Up, and Adherence
All participants contributed to analyses of mortality. Vital
status was unknown for only three participants, who could
not be contacted at the time of treatment suspension or
within a 6-mo window before or after that time. Of the
participants, 2,500 (98.9%) had follow-up for nonfatal events.
Participants contributed 4,660 person-years of follow-up
through 17 January 2005 (1,346 for celecoxib, 1,332 for
naproxen, and 1,982 for placebo). The median follow-up
times for the three treatment groups were 23.3, 23.5, and 22.1
mo, respectively. Median times of administration of the study
drug were 16.1, 14.0, and 15.6 mo, respectively (p ¼ 0.32).
Outcomes and Estimation
Table 2 presents deaths (counts and cumulative 3-y incidence)
by treatment group through 17 January 2005. Mortality was
low, considering participant ages. The hazard ratio point
estimates for the active treatments compared to placebo
exceeded 1.00 for overall mortality and for cardiovascular
and cerebrovascular deaths, but the corresponding 95% CIs
were wide. Table 3 shows the hazard ratios for fatal and
nonfatal MI, stroke, CHF, and TIA and for our sequential
composite outcomes, and Figure 2 is a Kaplan-Meier graph of
the cumulative incidence over time for the full composite
outcome. For celecoxib, the hazard ratios exceeded 1.00 for
two of the four individual events, and the composite
outcomes were only slightly elevated, none of them at a level
of conventional statistical signiﬁcance. For naproxen, the
hazard ratios were elevated for each individual cardiovascular
and cerebrovascular event, again with wide CIs. As these
event categories were sequentially combined with cardiovas-
Figure 1. Participant Flow Diagram
doi:10.1371/journal.pctr.0010033.g001
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the hazard ratios converged around a point estimate of an
approximate 60% increase in risk, and the boundary of
conventional statistical signiﬁcance was crossed.
Ancillary Analyses
Hazard ratios were similar for secondary analyses that
considered only the time during which participants were
administered study treatments. Analyses stratiﬁed for base-
line use of aspirin showed the highest risk among those in the
naproxen group who were not taking aspirin, but the tests of
interaction by aspirin use were not signiﬁcant for either drug
(p ¼ 0.56 for celecoxib and p ¼ 0.59 for naproxen).
Of the 1,521 participants who reported that they were not
receiving treatment for hypertension at baseline, 471 newly
reported receiving treatment for hypertension during follow-
.......................................................................................................................................................................................
Table 1. Study Population at Entry
Characteristic Subcategory Total Celecoxib Naproxen Placebo
Number randomized 2,528 726 719 1,083
Age (percentiles, years) 50 74 74 74 74
25,75 72,77 72,77 72,77 72,77
0,100 70,90 70,90 70,88 70,90
Gender (%) Female 45.9 47.1 45.9 45.1
Male 54.1 52.9 54.1 54.9
Ethnic group (%) White, non-Hispanic 97.0 96.1 97.1 97.4
African-American 1.5 1.8 1.8 1.0
Hispanic 0.7 1.4 0.3 0.6
Other 0.8 0.6 0.7 0.9
Declined to answer 0.1 0.1 0.1 0.1
Marital status (%) Married 71.9 70.2 75.0 71.0
Widowed 18.2 19.7 16.1 18.7
Divorced/separated 7.3 7.3 6.1 8.0
Single 2.6 2.8 2.8 2.3
Education (%) Less than high school degree 4.0 3.9 4.9 3.6
High school degree 19.9 20.8 17.5 20.9
College, no degree 27.5 27.7 28.4 26.8
College degree 19.2 19.2 17.0 20.6
Postgraduate degree 29.4 28.5 32.3 28.2
Karnofsky (%) % scoring 100 82.3 84.3 80.1 82.5
% scoring 90 15.3 13.5 18.2 14.6
% scoring 80 2.2 2.1 1.4 2.8
% scoring 60–70 0.2 0.1 0.3 0.2
Aspirin use (%) 56.1 57.0 56.2 55.4
Hypertension treatment (%) Never 57.5 57.2 58.3 57.2
Past 2.7 3.4 2.5 2.3
Current 39.8 39.4 39.2 40.5
History (%) MI 5.1 5.4 3.8 5.9
Stroke 1.1 1.5 1.0 1.0
CHF 0.9 1.4 0.7 0.6
TIA 3.5 3.2 3.2 3.9
Peptic ulcer 4.4 4.3 4.6 4.3
Smoking status (%) Current 2.9 3.4 2.6 2.8
Past 52.6 50.1 50.4 55.9
Never 44.4 46.4 47.0 41.4
doi:10.1371/journal.pctr.0010033.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................................................................................................................
Table 2. Incidences and Hazard Ratios for Deaths by Treatment Group
Celecoxib Naproxen Placebo
Number randomized 726 719 1,083
Incidence of Death Events (3-y Incidence) (%)
a Celecoxib vs. Placebo Naproxen vs. Placebo
Celecoxib Naproxen Placebo Hazard
Ratio
95%CI p-Value Hazard
Ratio
95%CI p-Value
All deaths (n ¼ 32) 9 (1.70) 11 (2.22) 12 (2.00) 1.11 0.47–2.64 0.81 1.37 0.60–3.10 0.45
Cardiovascular deaths (n ¼ 10) 4 (0.78) 3 (0.47) 3 (0.66) 1.96 0.44–8.76 0.38 1.48 0.30–7.32 0.63
Cancer deaths (n ¼ 13) 4 (0.73) 5 (1.14) 4 (0.50) 1.49 0.37–5.96 0.57 1.86 0.50–6.93 0.35
Other deaths (n ¼ 9) 1 (0.21) 3 (0.63) 5 (0.84) 0.29 0.03–2.53 0.27 0.88 0.21–3.75 0.90
Hazard ratios, CIs, and p-values were obtained using Cox proportional hazards regression of the first occurrence of events.
a 3-y incidence is the percentage of participants experiencing the event by 3 y after randomization, as estimated with the Kaplan-Meier method.
doi:10.1371/journal.pctr.0010033.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3. Incidences and Hazard Ratios for First Occurence of Events by Treatment Group
Celecoxib Naproxen Placebo
Number with follow-up data 717 713 1,070
Event Subcategory
(Number of Events)
Events (3-y Incidence) (%)
a Celecoxib vs. Placebo Naproxen vs. Placebo
Celecoxib Naproxen Placebo Hazard
Ratio
95%CI p-
Value
Hazard
Ratio
95%CI p-
Value
Cardio/cerebrovascular events MI (34) 8 (1.80) 13 (2.19) 13 (2.01) 0.91 0.38–2.19 0.83 1.49 0.69–3.22 0.31
Stroke (24) 7 (1.05) 10 (2.38) 7 (1.23) 1.47 0.52–4.20 0.47 2.13 0.81–5.60 0.12
CHF (18) 3 (0.73) 8 (1.51) 7 (0.85) 0.63 0.16–2.44 0.50 1.70 0.62–4.69 0.30
TIA (27) 8 (1.55) 9 (2.20) 10 (1.35) 1.08 0.42–2.78 0.87 1.34 0.55–3.31 0.52
Composite events CV death/MI (39) 11 (2.41) 13 (2.19) 15 (2.52) 1.08 0.50–2.36 0.84 1.29 0.61–2.72 0.50
CV death/MI/stroke (62) 17 (3.26) 23 (4.54) 22 (3.74) 1.14 0.61–2.15 0.68 1.57 0.87–2.81 0.13
CV death/MI/stroke/ CHF (79) 20 (4.00) 31 (6.05) 28 (4.46) 1.06 0.60–1.88 0.85 1.66 1.00–2.77 0.05
CV death/MI/stroke/ CHF/ TIA (105) 28 (5.54) 40 (8.25) 37 (5.68) 1.10 0.67–1.79 0.72 1.63 1.04–2.55 0.03
Aspirin Aspirin use at baseline (45) 14 (8.40) 15 (9.58) 16 (7.55) 1.24 0.60–2.58 0.56 1.40 0.69–2.83 0.35
No aspirin use at baseline (60) 14 (4.30) 25 (7.87) 21 (4.87) 0.98 0.50–1.92 0.95 1.81 1.01–3.24 0.04
Hazard ratios, CIs, and p-values were obtained using Cox proportional hazards regression of the first occurrence of events.
a 3-y incidence is the percentage of participants experiencing the event by 3 y after randomization, as estimated with the Kaplan-Meier method.
doi:10.1371/journal.pctr.0010033.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. Graph of Time to Cardiovascular Death, MI, Stroke, CHF, or TIA
doi:10.1371/journal.pctr.0010033.g002
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for the groups assigned to celecoxib, naproxen, and placebo.
Both study treatments were associated with a substantial and
highly signiﬁcant increase in newly reported treatment for
hypertension.
DISCUSSION
Interpretation
For celecoxib, the ADAPT safety results showed no consistent
tendencytowardincreasedordecreasedriskforcardiovascular
and cerebrovascular events. Composite outcomes showed only
slightly increased estimates that were not statistically signiﬁ-
cantbut,iftrue,wouldbeclinicallysigniﬁcantwhenappliedto
the large population of celecoxib users. The ADAPT naproxen
results showed moderately elevated risks for all four cardio-
vascular and cerebrovascular events analyzed, and the CIs for
the composite outcomes narrowed as additional events were
included.Bothdrugswereassociatedwithincreasedindication
for antihypertensive treatment.
As noted above, these results must be interpreted in the
context of a trial that was stopped early, with small numbers of
events that were not originally intended as speciﬁc outcomes.
Therefore, our intention is not to present the ADAPT data as
being conclusive, but rather to make them available to the
general medical and research community and to the public at
large as a contribution to the growing body of knowledge from
placebo-controlled trials of COX-2 inhibitors and to the more
sparse knowledge from placebo-controlled trials regarding
conventional NSAIDs, as reviewed below.
Generalizability
ADAPT participants are a select population by virtue of their
family history of Alzheimer-like dementia, their high educa-
tional achievement, and their relatively healthy status, as
evidenced by the low rates of cardiovascular disease (CVD) at
entry and the low mortality rate observed during the trial.
However, these factors limit generalizability only to the
extent that they modify the treatment effect. There has been
speculation that any increased cardiovascular risk from anti-
inﬂammatory drugs may be conﬁned to those at higher risk of
disease, but there is little rationale for or evidence of
differing response to anti-inﬂammatory treatment.
Overall Evidence
The cardiovascular safety of COX-2 inhibitors has been
questioned since the publication of the Vioxx Gastrointesti-
nal Outcomes Research (VIGOR) trial results in late 2000, in
which rofecoxib (Vioxx) was associated with a 5-fold
increased risk of MI [7]. The Celecoxib Long-term Arthritis
Safety Study (CLASS) did not show an elevated cardiovascular
risk with celecoxib use [8], but CLASS differed from VIGOR
in that use of low-dose aspirin for cardioprotection was
allowed (as in ADAPT), and the comparator treatments
included ibuprofen, a compound later thought to mitigate
the cardioprotective effects of aspirin [9,10]. A class effect of
COX-2 inhibiting drugs was subsequently suggested [11,12].
The absolute annualized rates of cardiovascular events in
VIGOR and CLASS were similar, and both rates were higher
than those obtained from pooling the placebo groups from
several large primary prevention trials [12]. Nevertheless, a
2003 meta-analysis of all clinical trials with celecoxib did not
show increased cardiovascular risk compared to NSAID use
or placebo (though only six trials of 4- to12-wk duration were
placebo controlled, resulting in just 200 person-years of
exposure to placebo and three events) [13]. Also, a large
observational study in a Kaiser Permanente database showed
decreased odds of MI with celecoxib, but a 3-fold increased
odds with use of rofecoxib compared to remote use of
NSAIDs [14].
On 30 September 2004 Merck withdrew rofecoxib from the
market, after results from the Adenomatous Polyp Prevention
on Vioxx (APPROVe) trial showed a statistically signiﬁcant
relative risk for thrombotic events of 1.92 for rofecoxib
compared with placebo [15]. On 15 October 2004 Pﬁzer
announced that its drug valdecoxib (Bextra) appeared to
i n c r e a s et h er i s ko fc a r d i o v ascular events when given
following coronary artery bypass grafting (relative risk ¼
3.7, as later published) [16]. The debate continued as to
whether the cardiovascular risks observed were drug speciﬁc
or represented a class effect of COX-2 inhibitors [17,18].
Then, on 17 December 2004, the APC trial announced its
early termination because of observed hazard ratios for
cardiovascular death, MI, stroke, or heart failure of 2.3 with
200 mg b.i.d. celecoxib and 3.4 with 400 mg b.i.d. celecoxib,
compared to placebo [5]. Although the Pﬁzer-sponsored
Prevention of Sporadic Adenomatous Polyps (PreSAP) trial
was reported not to have shown increased risk with celecoxib
use, it too was terminated. At that point, the ADAPT Steering
Committee, in consultation with the NIA and the chair of the
Treatment Effects Monitoring Committee, voted to suspend
treatment with celecoxib because the same dosage produced
notable cardiovascular risk in the APC trial. The FDA put a
full clinical hold on prevention trials with celecoxib 6 d later.
.......................................................................................................................................................................................
Table 4. Incidences and Hazard Ratios for Initiation of Hypertension Therapy by Treatment Group
Celecoxib Naproxen Placebo
Number not being treated for hypertension at baseline 440 437 644
Events (3-y Incidence) (%)
a Celecoxib vs. Placebo Naproxen vs. Placebo
Celecoxib Naproxen Placebo Hazard
Ratio
95%CI p-
Value
Hazard
Ratio
95%CI p-
Value
Incident treatment for hypertension (n ¼ 471) 160 (47.43) 147 (45.00) 164 (34.08) 1.56 1.26–1.94 ,0 .0001 1.40 1.12–1.75 0.003
Hazard ratios, CIs, and p-values were obtained using Cox proportional hazards regression of the first occurrence of events.
a 3-y incidence is the percentage of participants experiencing the event by 3 y after randomization, as estimated with the Kaplan-Meier method.
doi:10.1371/journal.pctr.0010033.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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the only peer-reviewed publication speciﬁcally reporting on
cardiovascular events from a placebo-controlled trial of
celecoxib; results from the PreSAP trial, including cardiovas-
cular events, have recently been published as well [19]. A
meta-analysis of COX-2 inhibitor trials, using data supplied
by the drug manufacturers or presented at the February 2005
FDA Joint Advisory Committee meeting, was recently
published [20]. The long-term placebo-controlled celecoxib
data were largely attributable to the APC and PreSAP trials.
However, other long-term placebo-controlled trials of cele-
coxib have been conducted. A systematic search of Clinical-
Trials.gov, MEDLINE, the Cochrane Library and CENTRAL
registry, and clinicalstudyresults.org identiﬁed 38 placebo-
controlled trials of celecoxib of 12 wk or longer duration. At
least 14 of these (of which ADAPT is one) appear to have
sample sizes of 100 or more and median treatment duration
of 1 y or more. A meta-analysis of such trials may lead to a
more precise estimate of the long-term risks of the
medication. A National Institutes of Health-led effort to
obtain cardiovascular and cerebrovascular outcome data
from such trials and to conduct a meta-analysis is underway.
While the ADAPT celecoxib data may be compared with
corresponding results from sister trials of similar size and
duration, our naproxen data stand alone. Several trials have
reported that naproxen produced lower cardiovascular risks
than comparator COX-2 inhibitor treatments, and the meta-
analysis by Kearney et al. [20] estimates the risk ratio for
COX-2 inhibitors compared to naproxen (500 mg b.i.d.) at
1.57. However, these results do not answer the question of
risk with naproxen use.
It has been suggested that naproxen, at least at higher
doses, produces lower cardiovascular risk than comparator
COX-2 drugs because of antithrombotic effects similar to
those of aspirin. Numerous observational studies have
investigated the association of naproxen use and CVD, and
a meta-analysis of eight case-control studies and three
retrospective cohort studies obtained a combined estimate
of 0.86 [21]. However, as was noted by FDA drug safety
researcher David Graham in his testimony on 17 February
2005 before the FDA Arthritis Advisory Committee and the
Drug Safety and Risk Management Advisory Committee [22],
the three cohort studies did not show a signiﬁcant protective
effect. Also, among the three case-control studies showing the
largest risk reduction, one compared naproxen use to other
NSAID use (primarily ibuprofen) rather than to no use or
remote use [23], another included subarachnoid hemorrhage
and subdural hematoma in a composite outcome [24], and the
third showed a similar cardioprotective effect for both
remote and current use of naproxen [25]. More recently,
several nested or population-based case-control studies have
shown moderately increased cardiovascular risk associated
with the use of naproxen [14,26,27]. Of course, these are all
observational studies that are subject to potential biases in
the use and selection of NSAID therapy.
Several published trials tested naproxen and placebo as
well as a COX-2 inhibitor, and three reported on the outcome
of incident hypertension [28–30]. One of these trials had a
sample size of 351 [28], and the other two had follow-up times
of 12 wk and 26 wk [29,30]. Though the numbers of events
were small, all three showed more hypertension with
naproxen than with placebo, consistent with results from
ADAPT. The meta-analysis by Kearney et al. [20] provides a
risk ratio estimate for naproxen compared to placebo of 0.92.
However, this estimate is obtained from trials with treatment
durations of 12 wk or less, with the exception of two of the
trials discussed above [28,30].
The ADAPT data on naproxen are by no means deﬁnitive.
Under ordinary circumstances, they would not have war-
ranted suspension of treatment in December 2004. Nonethe-
less, after the APC announcements, the ADAPT investigators
were fundamentally uncomfortable with continuing naprox-
en simply because highly publicized external circumstances
had spotlighted risks with celecoxib, but not with naproxen.
It has been suggested that all NSAIDs may have some degree
of cardiovascular risk [22,26,31], perhaps especially for those
not taking aspirin. The ADAPT naproxen data provide some
support to this theory, particularly for older adults. However,
without adequate evidence from long-term, placebo-con-
trolled trials, the measure of this risk remains a matter of
speculation.
There are several limitations in the ADAPT data. First,
because ADAPT was not designed to detect differences in
cardiovascular and cerebrovascular risks, the composite
outcomes were speciﬁed post hoc. We designed their
constituent events both to be as comparable as possible to
the approaches used in the Antiplatelet Trialists Collabo-
ration and the APC trials and to draw on outcomes collected
in a systematic manner from close-ended questions asked to
participants at every follow-up contact. Because ADAPT by
design focused on neurological events, we asked participants
speciﬁcally about the occurrence of both stroke and TIA.
Although we also asked about MI and CHF, we did not ask
speciﬁc questions about conditions such as unstable angina or
other indications for interventional cardiologic procedures
and therefore were not able to include them in our composite
of systematically collected outcomes.
We also did not have a priori procedures for adjudication
of cardiovascular or cerebrovascular events. Although we
could employ such procedures post hoc in an attempt to
increase the precision of reported events, these procedures
have several limitations. We cannot identify missed events,
and we cannot be certain that the process of adjudication is
not inﬂuenced by the current controversy. Therefore,
adjudication will only decrease the absolute risk observed
and could bias the relative risk. Also, adjudication may foster
a sense of precision that is inappropriate given the small
numbers of reported events in a trial that was terminated
early [32]. For these reasons, we have chosen to present what
we believe to be unbiased raw data that provide a valid
estimate of both the absolute and relative treatment effects.
Ultimately, the largest limitation in the ADAPT data is the
imprecision resulting from the small numbers of events. A
corresponding caution in their interpretation is warranted.
Even so, our actions, as well as those of other investigators
and the FDA, reﬂect the low tolerance for risk in primary
prevention trials. For their participants, the only beneﬁt of
the intervention is the possibility of later protection from a
condition they might have avoided in any case. This creates
some difﬁculty for extrapolation to the clinical setting, where
these drugs are used for pain relief in conditions such as
osteoarthritis and rheumatoid arthritis, and the potential
risks need to be weighed against the known immediate
beneﬁts of treatment. Nevertheless, we as a medical and
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research community are attempting just such difﬁcult
extrapolation, as the primary prevention setting is providing
long-term, placebo-controlled data for drugs approved on
the basis of short-term trials but used for the treatment of
chronic conditions frequently necessitating decades of
analgesic therapy. Therefore, we believe it is essential to
make data from long-term trials such as ADAPT available to
contribute to the larger body of evidence on drug safety.
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0010033.sd001 (47 KB DOC).
Trial Protocol: ADAPT Protocol, Version 1.4
Found at doi:10.1371/journal.pctr.0010033.sd002 (233 KB PDF).
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